Ascendis Pharma Reports Second Quarter 2026 Financial Results
In the second quarter of 2026, product revenue reached €315 million, showing a significant increase of 105% year-over-year. Out of this total, €252 million came from YORVIPATH®, €55 million from SKYTROFA®, and €8 million from YUVIWEL®.